)
Greg Timblin
CEO & Co-Founder,
Inapill
Inapill CEO and co-founder Dr. Greg Timblin has dual degrees in Chemistry and Biology from Nebraska Wesleyan University, and a Ph.D. in Molecular & Cell Biology from UC Berkeley. As an American Diabetes Association (ADA) postdoctoral fellow at UC Berkeley and UCSF, Dr. Timblin discovered novel strategies to therapeutically target immune cell metabolism in preclinical models of inflammatory disease, cancer, and chronic infection. Based in Bakar Bio Labs, Inapill was co-founded with the therapeutics team at General Inception, with the goal of developing 1st-in-class small molecule therapeutics against immunometabolic targets for improved treatment of inflammatory & autoimmune disease.
Sessions